Effect of combination pioglitazone with sodium-glucose cotransporter-2 inhibitors or glucagon-like peptide-1 receptor agonists on outcomes in type 2 diabetes: A systematic review, meta-analysis, and real-world study from an international federated database.
Matthew AnsonAlex E HenneySizheng S ZhaoGema H IbarburuGregory Yoke Hong LipDaniel J CuthbertsonKatarzyna NabrdalikUazman AlamPublished in: Diabetes, obesity & metabolism (2024)
Both our systematic review/meta-analysis and the real-world dataset show that combination of pioglitazone with either GLP-1RAs or SGLT2 inhibitors is associated with increased weight loss and reduced risk of heart failure compared with monotherapy.